SKB264 Clinical Trials

5 actively recruiting trials

▼ -3 trials since June 2026

Also known as: KL-A167

Pipeline

Phase 2: 2Phase 3: 3

Top Sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.4
Shanghai Jiao Tong University School of Medicine1

Indications

Cancer5
Breast Cancer4
Metastatic Breast Cancer2
Triple Negative Breast Cancer1
Lung Cancer1

Other5 trials

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase 3

Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer

Phase 2

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Phase 2

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.